The newest and most advanced model of Esperal-Implant was developed by our professional team back in 2011 in association with Injecs. Co. and Iridium Communications Inc. Injecs is the world leading manufacturer of needless injectors, and Iridium Communications Inc. partners with Satelles, a division of iKare Corporation, to provide communication services through satellite channels.

The key advantage of the Esperal-Implant is that it does not maintain the level of disulfiram in the patient’s blood. Opposite to the well-known Russian implant Torpedo, Esperal works in an awaiting regimen. The electronic alcohol testing device checks the level of alcohol in patients’ bloodstream every 15 minutes around the clock. That means that the patient’s blood is free from disulfiram, and any expectations of the side effects that this chemical leads to may be dismissed (as impossible). Only when the concentration of alcohol in a bloodstream rises above the allowed level does Esperal-Implant turn on and inject one crystal of dry, highly concentrated disulfiram into the local capillary system to initiate the disulfiram-ethanol reaction (DER). Once the reaction starts, it can’t be stopped until its natural completion (approximately 4-6 hours) when the Esperal-Implant switches back to its normal awaiting regimen.

Esperal-Implant was developed based on the latest discoveries of thin-film technology, which allows for the creation of microchips from bio-friendly materials that use bioelectricity from the surrounding tissues as a source of energy.

After approximately 4-5 years, these thin-film microchips get encapsulated by the nearby connective tissues and become inactive.